Kingsbury Capital Investment Advisors’s Coherus Oncology CHRS Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.4K	Buy	+12,396	New	+$20.2K	0.01%	121

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Kingsbury Capital Investment Advisors's CHRS Position: Q2 2026 in Review

Kingsbury Capital Investment Advisors opened a new position in Coherus Oncology (CHRS) in Q2 2026: 12,396 shares worth $17.4K. The stake represents 0.01% of the portfolio and ranks #121 among its holdings.

147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Kingsbury Capital Investment Advisors held 12,396 shares of Coherus Oncology worth $17.4K as of Q2 2026.
Coherus Oncology was a new Kingsbury Capital Investment Advisors position in Q2 2026.
Coherus Oncology made up 0.01% of Kingsbury Capital Investment Advisors's portfolio in Q2 2026, its #121 holding.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q2 2026, filed 25 Aug 2026.